During the corresponding time, Cellectis S A recorded a revenue increase by 75.76 % year on year, While revenue at the Cellectis S A 's corporate clients
Cellectis S A's Comment on Sales, Marketing and Customers
The company operates in the hematologic cancer market, focusing on advanced hematologic cancers including Acute Lymphoblastic Leukemia (ALL), Non-Hodgkin's Lymphoma (NHL), and Large B-Cell Lymphoma (LBCL). It develops Universal CAR T-cells (UCARTs) as off-the-shelf treatments targeting antigens on tumor cells. The company has collaborations and licensing agreements with Servier and Allogene, with Allogene holding exclusive rights in the U.S., EU, and UK for certain products. Customers and market participants mentioned in filings include Allogene, Calyxt, Cellectis, Cibus, and Servier.
Cellectis S A’s Comment on Sales, Marketing and Customers
The company operates in the hematologic cancer market, focusing on advanced hematologic cancers including Acute Lymphoblastic Leukemia (ALL), Non-Hodgkin's Lymphoma (NHL), and Large B-Cell Lymphoma (LBCL). It develops Universal CAR T-cells (UCARTs) as off-the-shelf treatments targeting antigens on tumor cells. The company has collaborations and licensing agreements with Servier and Allogene, with Allogene holding exclusive rights in the U.S., EU, and UK for certain products. Customers and market participants mentioned in filings include Allogene, Calyxt, Cellectis, Cibus, and Servier.
Sources:
Cellectis S a’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Cellectis S a’s corporate clients.
For your research, we’ve provided 9 tables on Cellectis S a corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
100 %